AFP and hepatocellular carcinoma: Using multibiomarker panels, the AUC for detecting HCC in CHB and LC patients are 0.953 and 0.966 in the discovery cohort and 0.891 and 0.818 in the validation cohort, respectively, while it is 0.717 and 0.683 when using AFP alone (Fig. 6, B and C; supplemental Table S17).